Medpace Holdings Stock Tumbles 17% On Q2 Earnings
Medpace Holdings Stock Tumbles 17% On Q2 Earnings
$Medpace (MEDP.US)$ shares are falling in Monday's after-hours session after the company reported mixed financial results and adjusted its forward guidance.
$Medpace (MEDP.US)$该公司发布了混合的财务业绩，并调整了向前的指导，导致股价下跌。
Q2 Revenue: $528.1 million, versus estimates of $528.44 million
Q2营业收入：5281万美元，预估值为5284万美元。
Q2 EPS: $2.75, versus estimates of $2.54
Q2每股收益：2.75美元，预估值为2.54美元。
Total revenue was up 14.6% on a year-over-year basis. Medpace said its backlog increased 13.7% year-over-year to $2.925 billion.
总营收同比增长14.6%。Medpace表示，在过去一年中，其积压订单增长了13.7%至29.25亿美元。
The company generated $116.4 million in cash flow during the quarter. Medpace ended the quarter with $510.9 million in cash and cash equivalents.
该公司本季度现金流量为1164万美元。Medpace在本季度结束时，现金及现金等价物为5,109万美元。
Outlook: Medpace revised its full-year 2024 revenue forecast from a range of $2.15 billion to $2.2 billion to a new range of $2.125 billion to $2.175 billion versus estimates of $2.17 billion.
展望未来：Medpace将其2024全年营收预测从21.5亿美元至22亿美元的区间修订为新的区间21.25亿美元至21.75亿美元，预估值为21.7亿美元。
In contrast, Medpace raised its full-year 2024 earnings outlook from a range of $10.79 to $11.47 per share to a new range of $11.24 to $11.93 per share versus estimates of $11.25 per share.
相比之下，Medpace将其2024全年每股收益展望从10.79美元至11.47美元的区间调高至新的区间11.24美元至11.93美元，预估值为每股11.25美元。